Condition: HIV Infections · Sponsor: Evandro Chagas National Institute of Infectious Disease
Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation strategies. The proposed implementation study will assess the safety and effectiveness of open label CAB LA PrEP when offered at public health facilities to cisgender men and transgender or gender non-binary individuals who have sex with persons assigned male at birth. The study will also evaluate two nested implementation strategies, an mHealth education and decision support tool and a WhatsApp injection appointment reminder. The study will also assess overall facilitators and barriers to integrating CAB LA into existing oral PrEP services.
This description comes directly from the study's public registry record.
Thiago Torres, Pharm D, PhD · +55213865-9573 · thiago.torres@ini.fiocruz.br
Brenda Hoagland, MD, PhD · +55213865-9122 · brenda.hoagland@ini.fiocruz.br
Always discuss trial participation with your own doctor first.
| Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ | Rio de Janeiro, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05515770